MindMed Near Term CATALYSTS & Nasdaq Debrief [MMED / MNMD]

So what happened with MindMed (MMED / MNMD) on the day on the NASDAQ uplisting? As we all know, MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER. Ever since, we all speculated on what will happen to the MindMed stock on April 27 and what will be it’s closing price? On April 26th, the stock price rose to near all time highs and a lot of retail investors thought that on the 27th, the run will continue. MindMed’s move to the Nasdaq was to increase the visibility of its stock in hopes of reaching out to a new group of retail and institutional investors. Unfortunately, the plan didn’t go so well. While MindMed opened at the previous all time high, the stock dropped throughout the day. MindMed, (MNMD) closed today after its first day on the Nasdaq at: $4.02, down 16%, most probably due to investors who took some profits, which was one of the scenarios in our previous video on MindMed Nasdaq Uplisting price predictions. So in this video, I’ll share my thoughts on today’s MMED / MNMD stock events and then discuss the near time future catalysts for MindMed. Timestamps: 0:00 - Intro 1:27 - Thoughts on MindMed (MNMD) first trading day on NASDAQ 6:05 - MindMed catalyst #1 - Atai's IPO 7:37 - PSIL ETF coming soon 9:58 - Phase 2a results for MindMed's Project LUCY 11:38 - Project LUCY starting Phase2b in Q4 this year 12:26 - Completion of Phase 1 Trial for Project Layla (18-MC) 13:08 - Completion of Phase 1 LSD Neutralizer Study Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor Links to Clinical trials : https://clinicaltrials.gov/ct2/results?cond=&term=LSD&cntry=&state=&city=&dist= https://clinicaltrials.gov/ct2/show/NCT03153579?term=LSD&draw=2&rank=5&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD&draw=2&rank=6&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY https://mindmed.co/wp-content/uploads/2021/04/MindMed-Corporate-Presentation-4.27.2021.pdf DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #MindMedNasdaq #MindMedstock

Interview With Joshua Bartch

Mydecine Innovations Group’s Director, CEO & Co-Founder, Joshua Bartch chats with our Director of Content, Jill Ettinger.

Psychedelic Business Roundup- Is California Next For Legalizing Psychedelics?

April 26, 2021- This week's Psychedelic Business News Round Up's top stories include: - California's move to decriminalize psychedelics - Silo Wellness is expanding into the German Stock Exchange - Daniel Carcillo’s Psychedelic Startup…

Psychedelic Spotlight Interview with Douglas K. Gordon

Psychedelic Spotlight Interview with Douglas K. Gordon In this episode of the Psychedelic Spotlight podcast, we connect with Douglas K. Gordon, CEO of Silo Wellness, a wellness company in the psychedelics and functional mushroom marketplace.…
Who Is Stanislav Grof? Meet the Psychedelic Pioneer and Father of Holotropic Breathwork

Who Is Stanislav Grof? Meet the Psychedelic Pioneer and Father of Holotropic Breathwork

,
Stanislav Grof is one of the earliest pioneers in psychedelics and holotropic breathwork.
New Campaign to Raise Awareness of Healing Power of Psychedelics for Veterans

New Campaign to Raise Awareness of Healing Power of Psychedelics for Veterans

A new campaign, #natureheals promotes psychedelics for veterans suffering from PTSD and other mental health issues.
Kevin O'Leary-Backed MindMed Is 2nd Psychedelic Company to List On Nasdaq

Kevin O’Leary-Backed MindMed Will Be 2nd Psychedelic Company to List On Nasdaq

MindMed will take its Kevin O'Leary-backed platform onto the Nasdaq Tuesday as only the 2nd psychedelic company to do so.
Fireside Project Launches Psychedelic Support Hotline

Fireside Project Launches Psychedelic Peer Support Hotline

A new psychedelic hotline, the Fireside Project, aims to provide peer support for people under the influence of psychedelic substances.
The Benefits of Peyote: Ancient Wisdom, Modern Medicine

The Benefits of Peyote: Ancient Wisdom, Modern Medicine

,
The benefits of peyote have been prized by Indigenous cultures for millennia. Now they're showing promise in modern medicine, too.

MindMed Nasdaq Uplisting STOCK PREDICTIONS // How Far will MindMed Go? [MMED/ MMEDF]

Here are my MindMed NASDAQ uplisting STOCK PREDICTIONS! MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER. On the day the news was announced, MMED and MMEDF gained 65.26% , rising from $2.13 to a day high of to $3.57 Though in the last few days the price had fallen, it was still up by 30.86% over the past 2 weeks. MindMed volume increased on the last day, in total, 14 million more shares were traded that the day before. This giant bump brought a lot of MindMed stock speculation which is why we’re making this episode. Where does MindMed go from here on? MMED / MNMD is still just at the beginning of their long-term growth trajectory so we could only do our due diligence while speculating. Some speculate that some investors might feel inclined to take profits, which is absolutely understandable. But will they take profits right away or wait for the MNMD price to go ballistic or take profits right away? What will happen to the MindMed stock when/if the do? Others speculate that the uplisting event might create a FOMO movement which could more than 3X the stock’s price which could create a larger FOMO wave and bring MindMed’s stock price to a similar level to Compass Pathways who’s market cap is very close to MindMed’s. On this channel, we have been repeatedly saying that investing in the psychedelic industry and specifically in Mindmed should be a long-term play and that the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval. So…. In this segment, we’ll discuss FOUR possible cases: Timestamps: 0:00 - Intro 4:17 - Worst Case 7:48 - Probable Case 9:57 - #WINNING CASE 11:58 - APES TOGETHER STRONG CASE Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #MindMedNasdaq #MindMedstock